🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

United Therapeutics director Rothblatt sells over $1.9m in stock

Published 2024/05/28, 22:40

United Therapeutics (NASDAQ:UTHR) Corporation (NASDAQ:UTHR) director Martine A. Rothblatt has completed a series of transactions involving the company's shares, according to recent SEC filings. Rothblatt sold a total of $1,973,943 worth of common stock, with individual sale prices ranging from $270.92 to $277.27.

The transactions occurred on May 23 and 24, with Rothblatt selling varying amounts of shares over the two days. On May 23, the sales included 645 shares sold at a weighted average price of $274.50, 1,347 shares at $275.54, 1,247 shares at $276.36, 361 shares at $277.03, and on May 24, she continued with sales of 234 shares at $270.92, 1,959 shares at $272.01, 1,014 shares at $272.85, 146 shares at $273.94, 125 shares at $275.28, 88 shares at $276.63, and 34 shares at $277.27.

In addition to the sales, Rothblatt also exercised options to acquire 3,600 shares of common stock at a set price of $129.49 per share, totaling $932,328. These transactions were part of a pre-arranged 10b5-1 trading plan, which allows company insiders to set up a trading plan for selling stocks they own.

Following these transactions, Rothblatt's direct ownership in United Therapeutics stock has changed, but she also has indirect ownership through family trusts, as noted in the SEC filing footnotes. These trusts hold significant amounts of United Therapeutics shares, with one trust alone holding 245,909 shares.

Investors often monitor insider transactions as they can provide insights into the company's performance and insider perspectives on the stock's value. In the case of United Therapeutics, these recent filings provide a detailed look at the trading activities of one of its directors.

InvestingPro Insights

In light of the recent insider transactions at United Therapeutics Corporation (NASDAQ:UTHR), investors seeking a deeper understanding of the company's financial health can find valuable insights through InvestingPro metrics. The company boasts a robust Market Cap of $11.94B and an attractive P/E Ratio that stands at 12.05. More impressively, when adjusted for the last twelve months as of Q1 2024, the P/E Ratio tightens to 11.59, suggesting a company that is reasonably valued relative to its earnings.

United Therapeutics also demonstrates a strong operational performance with a Gross Profit Margin of 88.87% over the same period, highlighting its efficiency in managing costs relative to revenue. Furthermore, the company's Revenue Growth was notable at 26.09% for the last twelve months as of Q1 2024, indicating a healthy expansion in its financials.

From the perspective of InvestingPro Tips, two standout points for United Therapeutics include the aggressive share buyback strategy by management and the company's solid liquidity position, holding more cash than debt on its balance sheet. These factors, combined with the company's low price volatility and strong returns over the last month and three months, may signal confidence in the company's future performance. Additionally, with analysts revising their earnings upwards for the upcoming period and a prediction of profitability for the year, the recent insider transactions may be seen in a broader strategic context.

For those interested in exploring further, InvestingPro offers additional tips on United Therapeutics, providing a comprehensive analysis for investors. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to an even more extensive range of financial metrics and expert insights. With 15 additional InvestingPro Tips available, investors can make more informed decisions backed by real-time data and expert analysis. Visit https://www.investing.com/pro/UTHR to learn more.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.